{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:16:38Z","timestamp":1772507798415,"version":"3.50.1"},"reference-count":33,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Amyloid-positron emission tomography (PET) imaging (API) detects amyloid-beta pathology early in the course of Alzheimer\u2019s disease (AD) with high sensitivity and specificity. (18)F-florbetapir (Amyvid) is an amyloid-binding PET ligand with a half-life suitable for clinical use outside of the research setting. How API affects patient investigation and management in the \u2018real-world\u2019 arena is unknown. To address this, we retrospectively documented the effect of API in patients in the memory clinic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed the presenting clinical features, the pre-API and post-API investigations, diagnosis and outcomes for the first 100 patients who had API as part of their routine work-up at the Imperial Memory Centre, a tertiary referral clinic in the UK National Health Service.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>API was primarily used to investigate patients with atypical clinical features (56 cases) or those that were young at onset (42 cases). MRI features of AD did not always predict positive API (67%), and 6 of 23 patients with MRIs reported as normal were amyloid-PET positive. There were significantly more cases categorised as non-AD dementia post-API (from 11 to 23). Patients investigated when API was initially available had fewer overall investigations and all patients had significantly fewer investigations in total post-API.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>API has a clear impact on the investigation of young-onset or complex dementia while reducing the overall burden of investigations. It was most useful in younger patients, atypical presentations or individuals with multiple possible causes of cognitive impairment.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2017-316194","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:50:22Z","timestamp":1507683022000},"page":"294-299","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":47,"title":["Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients"],"prefix":"10.1136","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9007-7017","authenticated-orcid":false,"given":"Christopher James","family":"Carswell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarni","family":"Win","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty","family":"Muckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angus","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Dawe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara D","family":"Barwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paresh A","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"2020050722291854000_89.3.294.1","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31824b211b"},{"key":"2020050722291854000_89.3.294.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70090-0"},{"key":"2020050722291854000_89.3.294.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"2020050722291854000_89.3.294.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.3.461"},{"key":"2020050722291854000_89.3.294.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821a44dd"},{"key":"2020050722291854000_89.3.294.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.120618"},{"key":"2020050722291854000_89.3.294.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70077-1"},{"key":"2020050722291854000_89.3.294.8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/13506129.2014.926267","article-title":"Use of amyloid PET across the spectrum of Alzheimer\u2019s disease: clinical utility and associated ethical issues","volume":"21","author":"Leuzy","year":"2014","journal-title":"Amyloid"},{"key":"2020050722291854000_89.3.294.9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12916-015-0404-6","article-title":"Amyloid imaging for dementia in clinical practice","volume":"13","author":"O\u2019Brien","year":"2015","journal-title":"BMC Med"},{"key":"2020050722291854000_89.3.294.10","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22068"},{"key":"2020050722291854000_89.3.294.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.069088"},{"key":"2020050722291854000_89.3.294.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.2008"},{"key":"2020050722291854000_89.3.294.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70142-4"},{"key":"2020050722291854000_89.3.294.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.02.004"},{"key":"2020050722291854000_89.3.294.15","doi-asserted-by":"publisher","DOI":"10.1186\/2051-5960-2-46"},{"key":"2020050722291854000_89.3.294.16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1750-1326-9-10","article-title":"A consecutive case series experience with [18\u2009F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition","volume":"9","author":"Mitsis","year":"2014","journal-title":"Mol Neurodegener"},{"key":"2020050722291854000_89.3.294.17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0000000000002576","article-title":"& Alzheimer\u2019s Disease neuroimaging Initiative. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI","volume":"86","author":"Landau","year":"2016","journal-title":"Neurology"},{"key":"2020050722291854000_89.3.294.18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181b23564"},{"key":"2020050722291854000_89.3.294.19","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e318279d02a"},{"key":"2020050722291854000_89.3.294.20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaneurol.2016.3751","article-title":"Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET With [18F]-florbetapir (INDIA-FBP) study","volume":"73","author":"Boccardi","year":"2016","journal-title":"JAMA Neurol"},{"key":"2020050722291854000_89.3.294.21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3233\/JAD-132561","article-title":"Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort","volume":"41","author":"Zwan","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"2020050722291854000_89.3.294.22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000032"},{"key":"2020050722291854000_89.3.294.23","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610202008281"},{"key":"2020050722291854000_89.3.294.24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/brain\/123.3.484","article-title":"Atypical and typical presentations of Alzheimer\u2019s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases","volume":"123 Pt 3","author":"Galton","year":"2000","journal-title":"Brain"},{"key":"2020050722291854000_89.3.294.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70159-9"},{"key":"2020050722291854000_89.3.294.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2013.03.014"},{"key":"2020050722291854000_89.3.294.27","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww015"},{"key":"2020050722291854000_89.3.294.28","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid \u03b2-amyloid 42: a cross-validation study against amyloid positron emission tomography","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol"},{"key":"2020050722291854000_89.3.294.29","first-page":"380","article-title":"Do cerebrospinal fluid transfer methods affect measured amyloid \u03b242, total tau, and phosphorylated tau in clinical practice?","volume":"1","author":"Paterson","year":"2015","journal-title":"Alzheimers Dement"},{"key":"2020050722291854000_89.3.294.30","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.81"},{"key":"2020050722291854000_89.3.294.31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3233\/JAD-160302","article-title":"Diagnosing dementia in the clinical setting: can amyloid PET provide additional value over cerebrospinal fluid?","volume":"54","author":"Weston","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"2020050722291854000_89.3.294.32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/YCO.0000000000000179","article-title":"Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease: current limitations and recent developments","volume":"28","author":"Zetterberg","year":"2015","journal-title":"Curr Opin Psychiatry"},{"key":"2020050722291854000_89.3.294.33","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23908"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2017-316194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:08:37Z","timestamp":1601057317000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2017-316194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,2,19]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1136\/jnnp-2017-316194"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2017-316194","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,10]]}}}